More information: Mark Boguniewicz et al, Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities, Advances in Therapy (2024). DOI: 10.1007/s12325-024 ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.